BioProcess International featured an article on Abzena’s recent launch of AbZelect & AbZelectPRO cell line development platforms.
Title: Abzena launches tech aimed at speeding up cell line development
Abzena claims its new platforms AbZelect and AbZelectPro can reduce the cell line development process (CLD) from 12 months to 15 weeks.
According to the firm, the platforms combine a speedy yet stringent selection regime to rapidly generate stable pools, an improved Chinese hamster ovary (CHO) host and advanced microfluidic technologies to conduct high throughput screening of the transfected cell population.
This process allows the platforms to isolate and rank 10s or 100s of thousands of individual cells for monoclonal antibodies (mAb) productivity, exporting only the best producers for further expansion characterization, reducing timelines from deoxy ribonucleic acid (DNA) to research cell bank (RCB) to only 15 weeks.
Access the full article here